Lester Thomas Email and Phone Number
I joined the biopharma industry in 1991 working on fludarabine for CLL and interferon beta for MS. Over the years, I've had the chance to work on nearly every type of platform: NCE’s, small and large molecules, monoclonal antibodies, a few medical devices, and various combinations of some or all of these. I've worked in both early and late-stage development in both very small (West Coast) and, now, very large (East Coast) organizations. My main focus currently is global regulatory strategy and team leadership in the immunology space.
-
Executive Regulatory Sciences Director, Immunology FranchiseAstrazeneca Oct 2019 - PresentCambridge, Cambridgeshire, GbI currently lead a team of 10 Director & Sr Director level regulatory leaders (GRLs) charged with progressing AZ's biopharmaceutical portfolio in the Respiratory & Immunology TA. My team is accountable for all aspects for regulatory strategy and health authority engagement for three globally marketed monoclonal antibody products.
-
Senior Director Regulatory AffairsAstrazeneca May 2018 - Sep 2019Cambridge, Cambridgeshire, GbI was the global regulatory strategy lead for the Aerospheres product franchise including, BEVESPI and BREZTRI.
-
Director Regulatory AffairsPearl Therapeutics Jul 2015 - Apr 2018Basking Ridge, New Jersey, UsAmong other things, I was the GRL for the FASENRA (benralizumab) severe eosinophilic asthma program, where I led the global marketing applications through to first approvals. Pearl was acquired by AstraZeneca in 2014 prior to my joining, and has since been absorbed fully into AZ. -
Director Global Regulatory AffairsGlaxosmithkline Jun 2007 - Jun 2015Brentford, Middlesex, GbI was the Global Regulatory Leader for TRELEGY® (ICS/LABA/LAMA triple combination) in COPD, from inception through Phase III. Prior to that, I worked on a variety of development stage assets in neuroscience, inflammation, and ophthalmology. -
Director Regulatory AffairsSyngenta Biotechnology Jan 2005 - Jun 2006Basel, Basel, ChLeader for all global regulatory activities related to development-stage biopharmaceutcals portfolio. -
Associate Director, Regulatory AffairsNektar Therapeutics Sep 1999 - Dec 2002San Francisco, California, Us -
Senior ConsultantPacific Biodevelopment Jan 1997 - Sep 1999Davis, Ca, Us -
Manager Regulatory AffairsXoma Corporation Nov 1994 - Jan 1997Emeryville, California, UsI managed a small group responsible for all global regulatory activities. I led all the early work on Raptiva (anti-CD11a MAb). -
Ra AssociateJohnson & Johnson Apr 1992 - Nov 1994New Brunswick, Nj, UsI supported the MAA for AMPHOTEC and the NDA for DOXIL while at what was then known as Liposome Technology, Inc. (LTI)LTI later changed it's name to Sequus, then Sequus was acquired by Alza. Alza was later acquired by J&J. -
Qa AuditorBayer Apr 1991 - Apr 1992Leverkusen, North Rhine-Westphalia, DeI supported the post-approval CMC commitments for FLUDARA (fludarabine phosphate) while at Triton/Berlex Biosciences. Later, Berlex was acquired by Bayer.
Lester Thomas Education Details
-
University Of Colorado BoulderBiology -
Mercersburg Academy
Frequently Asked Questions about Lester Thomas
What company does Lester Thomas work for?
Lester Thomas works for Astrazeneca
What is Lester Thomas's role at the current company?
Lester Thomas's current role is Executive Regulatory Sciences Director at AstraZeneca.
What schools did Lester Thomas attend?
Lester Thomas attended University Of Colorado Boulder, Mercersburg Academy.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial